Inhibikase Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.9%.

Top 18 shareholders own 27.3% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
12.3%	Milton Werner	889,242	€1.0m	0%	no data
8.17%	Armistice Capital LLC	589,575	€675.5k	0%	0.02%
3.1%	FiveT Capital AG	223,500	€256.1k	0%	100.0%
1.61%	William Blair Investment Management, LLC	116,120	€133.0k	51.6%	no data
0.53%	Citadel Advisors LLC	37,895	€43.4k	0%	no data
0.52%	Geode Capital Management, LLC	37,330	€42.8k	30.1%	no data
0.29%	Renaissance Technologies LLC	20,822	€23.9k	-2.8%	no data
0.23%	The Vanguard Group, Inc.	16,724	€19.2k	0%	no data
0.15%	Timber Point Capital Management LLC	11,000	€12.6k	0%	0.09%
0.14%	State Street Global Advisors, Inc.	10,084	€11.6k	0%	no data
0.1%	Flagship Consulting Inc	7,357	€8.4k	0%	no data
0.079%	Tower Research Capital Europe Limited	5,736	€6.6k	107%	no data
0.028%	Securities America Advisors, Inc.	2,000	€2.3k	0%	no data
0.023%	Morgan Stanley, Investment Banking and Brokerage Investments	1,667	€1.9k	0%	no data
0.0091%	Joseph Frattaroli	658	€754.0	0%	no data
0.0046%	The Mather Group, LLC	334	€382.8	0%	no data
0.0023%	Wells Fargo & Company, Securities and Brokerage Investments	167	€191.0	0%	no data
0.00058%	Bank of America Corporation, Asset Management Arm	42	€48.0	0%	no data